The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
An important new area of antidepressant drug development involves targeting the nicotinic acetylcholine receptor (nAChR). This receptor, which is distributed widely in regions of the brain associated with depression, is also implicated in other important processes that are relevant to depression, such as stress and inflammation. The two classes of drugs that target nAChRs can be broadly divided into mecamylamine- and cytisine-based compounds. These drugs probably exert their effects via antagonism at α 4 β 2 nAChRs, and strong preclinical data support the antidepressant efficacy of both classes when used in conjunction with other primary antidepressants (e.g., monoamine reuptake inhibitors). Although clinical data remain limited, preliminary results in this area constitute a compelling argument for further evaluation of the nAChR as a target for future antidepressant drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · cited 1×
“Large clinical trials for smoking cessation showed improvement in depressive symptoms associated with nicotine withdrawal [54, 55], and subsequent examinations found improved mood and cognition in subjects using varenicline for smoking cessation [56].”
BackgroundGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 1×
“Large clinical trials for smoking cessation showed improvement in depressive symptoms associated with nicotine withdrawal [54, 55], and subsequent examinations found improved mood and cognition in subjects using varenicline for smoking cessation [56].”
BackgroundThe role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“Their primary action is thought to be in the regulation of other neurotransmitter systems [8], particularly dopamine, via direct [9] and indirect effects [7, 10–13], and the n-methyl-D-aspartate (NMDA) glutamatergic system [14].”
BackgroundVarenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Brain nicotinic acetylcholine receptors: native subtypes and their relevance
Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882
PICCIOTTO, M., ADDY, N., MINEUR, Y., & BRUNZELL, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.005 · Cited by 460 · cited 1×
“Antidepressant effects of nicotine are thought to be due to initial activation of the nAChR, followed by rapid desensitization that leads to long-term antagonism [28–32].”
BackgroundNicotine addiction and comorbidity with alcohol abuse and mental illness
Dani, J. A., & Harris, R. A. (2005) · Nature Neuroscience · doi:10.1038/nn1580 · Cited by 382 · cited 1×
“The investigators additionally hypothesized that smokers would have a more robust response to mecamylamine, as nAChRs are thought to be upregulated in smokers due to chronic nicotine selfadministration [43].”
BackgroundNicotinic acetylcholine receptors as targets for antidepressants
Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., & Sanberg, P. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001035 · Cited by 279
Placebo-controlled trial of cytisine for smoking cessation
West, R., Zatonski, W., Cedzynska, M., Lewandowska, D., Pazik, J., Aveyard, P., & Stapleton, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102035 · Cited by 234
Regulation of Nicotinic Acetylcholine Receptor Numbers and Function by Chronic Nicotine Exposure
Gentry, C., & Lukas, R. (2002) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007023339184 · Cited by 232 · cited 1×
“Antidepressant effects of nicotine are thought to be due to initial activation of the nAChR, followed by rapid desensitization that leads to long-term antagonism [28–32].”
BackgroundVarenicline improves mood and cognition during smoking abstinence
Patterson, F., Jepson, C., Strasser, A. A., Loughead, J., Perkins, K. A., Gur, R. C., Frey, J. M., Siegel, S., & Lerman, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.028 · Cited by 222 · cited 1×
“Large clinical trials for smoking cessation showed improvement in depressive symptoms associated with nicotine withdrawal [54, 55], and subsequent examinations found improved mood and cognition in subjects using varenicline for smoking cessation [56].”
BackgroundAntidepressant effects of nicotine in an animal model of depression
Tizabi, Y., Overstreet, D. H., Rezvani, A. H., Louis, V. A., Clark Jr, E., Janowsky, D. S., & Kling, M. A. (1999) · Psychopharmacology · doi:10.1007/s002130050879 · Cited by 209 · cited 1×
“In rodents, several studies of nicotine administration have identified antidepressant-like effects during the forced swim test (FST) and tail suspension test (TST) [20–23], two preclinical models used to investigate potential antidepressant effects of candidate compounds [24, 25].”
BackgroundGunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009) · BMJ · doi:10.1136/bmj.b3805 · Cited by 200 · cited 1×
“Although one report found that varenicline was associated with an increased rate of such events [63], other large studies have generally found no difference between varenicline and other medications for smoking cessation [64–67], findings that have been replicated in studies sponsored by the U.”
ResultRollema, H., Shrikhande, A., Ward, K., Tingley III, F., Coe, J., O'Neill, B., Tseng, E., Wang, E., Mather, R., Hurst, R., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00682.x · Cited by 162 · cited 1×
“The preclinical profile of dianicline is similar to that of varenicline, with its ability to affect dopamine release [70], although it has relatively weak CNS penetration [71].”
BackgroundSuicidal Behavior and Depression in Smoking Cessation Treatments
Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027016 · Cited by 150
Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010) · Drug Safety · doi:10.2165/11319180-000000000-00000 · Cited by 142
Xiao, Y., Fan, H., Musachio, J. L., Wei, Z.-L., Chellappan, S. K., Kozikowski, A. P., & Kellar, K. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027318 · Cited by 141 · cited 1×
“Sazetidine-A is thought to act in a different manner than other cytisine analogues, in that it binds to and desensitizes α4β2 nAChRs without activation and acts principally on the β2 subunit [59, 73].”
BackgroundAntidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats
Semba, J., Mataki, C., Yamada, S., Nankai, M., & Toru, M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00477-0 · Cited by 140
Mineur, Y. S., Somenzi, O., & Picciotto, M. R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.01.006 · Cited by 137
Rabenstein, R. L., Caldarone, B. J., & Picciotto, M. R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0568-z · Cited by 129
George, T. P., Sacco, K. A., Vessicchio, J. C., Weinberger, A. H., & Shytle, R. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b49e · Cited by 128 · cited 1×
“[42] subsequently conducted an 8-week, double-blind, placebo-controlled trial of mecamylamine augmentation, administering mecamylamine 10 mg/day augmentation to patients with at least moderate depressive symptoms who had been on an SSRI for at least 3 months with little or no response.”
MethodCaldarone, B. J., Harrist, A., Cleary, M. A., Beech, R. D., King, S. L., & Picciotto, M. R. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.010 · Cited by 122
Effects of nicotine and mecamylamine on rat dorsal raphe neurons
Mihailescu, S., Palomero-Rivero, M., Meade-Huerta, P., Maza-Flores, A., & Drucker-Colı́n, R. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00658-x · Cited by 117
McClernon, F. J., Hiott, F. B., Westman, E. C., Rose, J. E., & Levin, E. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0516-y · Cited by 106 · cited 1×
“Complementing these experiments, clinical studies have shown that transdermal nicotine can improve mood in both depressed smokers [26] and nonsmokers [27].”
BackgroundAndreasen, J., Olsen, G., Wiborg, O., & Redrobe, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108091587 · Cited by 101 · cited 1×
“[38] MEC 3 or 10 mg/kga Improved FST/TST”
Bacher, I., Wu, B., Shytle, D. R., & George, T. P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903329102 · Cited by 96 · cited 1×
“While the results are not in the public domain, outcomes from the racemic mecamylamine trial were reportedly positive, and phase II results for smecamylamine were also reportedly positive, with a large effect size [6].”
ResultTurner, J. R., Castellano, L. M., & Blendy, J. A. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166280 · Cited by 88 · cited 11×
“Administration of the s-enantiomer of mecamylamine, s-mecamylamine, also resulted in improvement in FST and behavioral despair tests [40].”
ResultInfluentialRollema, H., Guanowsky, V., Mineur, Y. S., Shrikhande, A., Coe, J. W., Seymour, P. A., & Picciotto, M. R. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.002 · Cited by 87
Varenicline Augmentation in Depressed Smokers: An 8-Week, Open-Label Study
Philip, N. S., Carpenter, L. L., Tyrka, A. R., Whiteley, L. B., & Price, L. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04441 · Cited by 86
Self-citationAntidepressant Effect of Ingested Nicotine in Female Rats of Flinders Resistant and Sensitive Lines
Djurić, V. J., Dunn, E., Overstreet, D. H., Dragomir, A., & Steiner, M. (1999) · Physiology & Behavior · doi:10.1016/s0031-9384(99)00091-8 · Cited by 79
Cytisine-based nicotinic partial agonists as novel antidepressant compounds
Mineur, Y. S., Eibl, C., Young, G., Kochevar, C., Papke, R. L., Gündisch, D., & Picciotto, M. R. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.149609 · Cited by 75 · cited 2×
“Preclinical studies consistently have demonstrated antidepressant-like effects of cytisine in acute [39, 46] and chronic [39] rodent models.”
BackgroundBiological basis for the co-morbidity between smoking and mood disorders
Mineur, Y. S., & Picciotto, M. R. (2009) · Journal of Dual Diagnosis · doi:10.1080/15504260902869964 · Cited by 51
Caldarone, B. J., Wang, D., Paterson, N. E., Manzano, M., Fedolak, A., Cavino, K., Kwan, M., Hanania, T., Chellappan, S. K., Kozikowski, A. P., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2271-y · Cited by 47
Anderson, D. J., Malysz, J., Grønlien, J. H., El Kouhen, R., Håkerud, M., Wetterstrand, C., Briggs, C. A., & Gopalakrishnan, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.024 · Cited by 44 · cited 1×
“The preclinical profile of dianicline is similar to that of varenicline, with its ability to affect dopamine release [70], although it has relatively weak CNS penetration [71].”
BackgroundAndreasen, J. T., Redrobe, J. P., & Nielsen, E. Ø. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.11.004 · Cited by 43
Kozikowski, A. P., Eaton, J. B., Bajjuri, K. M., Chellappan, S. K., Chen, Y., Karadi, S., He, R., Caldarone, B., Manzano, M., Yuen, P., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200900079 · Cited by 36
Cited by
Neuroinflammation, Neurodegeneration, and Depression
Hurley, L. L., & Tizabi, Y. (2013) · Neurotoxicity Research · doi:10.1007/s12640-012-9348-1 · Cited by 259
Nicotinic acetylcholine receptors in neurological and psychiatric diseases
Terry, A. V., Jones, K., & Bertrand, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106764 · Cited by 90
Hannestad, J. O., Cosgrove, K. P., DellaGioia, N. F., Perkins, E., Bois, F., Bhagwagar, Z., Seibyl, J. P., McClure-Begley, T. D., Picciotto, M. R., & Esterlis, I. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.004 · Cited by 63
Hutson, P. H., Tarazi, F. I., Madhoo, M., Slawecki, C., & Patkar, A. A. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.005 · Cited by 31
“hippocampus •Mood (Philip et al., 2012)”
Metadata
- Authors
- Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H.
- Venue
- The Scientific World Journal
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-7
- ISSN
- 1537-744X (ISSN-L)
- OpenAlex
- W1978717872
- Cited by
- 44
- References
- 38
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.